PFE - Pfizer Decides To Raise COVID-19 Treatment Pill Price Defends Itself Amid Criticism for Cost Increase | Benzinga
Pfizer Inc (NYSE: PFE) is reportedly gearing up to price its Covid-19 drug Paxlovid at $1,390 for a five-day course, more than double what the U.S. government initially paid for it, at $529.
Pfizer's decision to raise the price has garnered criticism from doctors and patient advocates who fear limited patient access. The revelation of the list price is expected to intensify this criticism.
Last week, Pfizer slashed its full-year earnings and revenue guidance, citing decreasing demand for its COVID-19 products.
The reduced ...